Combination of SHetA2 with PRIMA-1MET, a drug that reactivates wild-type p53 apoptosis activity in mutant p53 proteins, also demonstrated complementary anti-cancer activity without toxicity in an orthotopic model of ovarian cancer maintenance therapy (Ramraj et al., 2019). Here, TP53 is linked to ovarian cancer.